InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Schilke Tobin, Chief Financial Officer. Director active across 1 companies, notably Revance Therapeutics, Inc.. Aggregated, 9 filings have been published. The latest transaction was disclosed on 15 March 2022 — Retenue fiscale. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations9 total
€37,6172,607 shares@ €14.429123.1% of flow
Common Stock
SEC:0001209191-22-019713:0·
€26,4612,241 shares@ €11.807516.3% of flow
Common Stock
SEC:0001479290-22-000021:0·
€26,4612,241 shares@ €11.807542.4% of flow
Common Stock
SEC:0001479290-22-000021·
€4,949404 shares@ €12.2497.9% of flow
Common Stock
SEC:0001479290-22-000002·
€4,949404 shares@ €12.2493.0% of flow
Common Stock
SEC:0001479290-22-000002:0·
€21,9971,556 shares@ €14.13735.2% of flow
Common Stock
SEC:0001479290-21-000177·
€21,9971,556 shares@ €14.13713.5% of flow
Common Stock
SEC:0001479290-21-000177:0·
€9,061446 shares@ €20.316714.5% of flow
Common Stock
SEC:0001479290-21-000132·
€9,061446 shares@ €20.31675.6% of flow
Common Stock
SEC:0001479290-21-000132:0·
9 of 9 declarations
About Schilke Tobin
Tobin Schilke is the Chief Financial Officer at Revance Therapeutics, Inc. He is responsible for financial management and corporate strategy. Schilke plays a key role in optimizing financial performance and strategic decision-making. His expertise is essential for ensuring the growth and profitability of the company.
